BUDGET IMPACT ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR HEAMOPHILIA A PATIENTS WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Souza, P. [1 ]
Puopolo, G. R. [1 ]
Leme-Souza, R. [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO36
引用
收藏
页码：S847 / S847
页数：1
相关论文
共 50 条
  • [31] BUDGET IMPACT ANALYSIS (BIA) OF RUXOLITINIB FOR TREATMENT OF INTERMEDIATE-2 OR HIGH RISK IPSS MYELOFIBROSIS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
    Nonino, A.
    Kim, H.
    Flora, A. P. A. D. S.
    VALUE IN HEALTH, 2021, 24 : S35 - S36
  • [32] THE ECONOMIC IMPACT OF REDUCING BLEEDING WITH EMICIZUMAB IN PATIENTS WITH HEMOPHILIA A AND FACTOR VIII INHIBITORS - BRAZILIAN CASE
    Segre, N.
    Mata, V
    Martins, T. D. C.
    VALUE IN HEALTH, 2022, 25 (12) : S165 - S165
  • [33] UMECLIDINIUM/VILANTEROL VERSUS TIOTROPIUM/OLODATEROL IN THE TREATMENT OF SEVERE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE: A BUDGET IMPACT ANALYSIS
    Araujo, M.
    Silva, D.
    Bernardino, G.
    VALUE IN HEALTH, 2023, 26 (06) : S93 - S93
  • [34] MODELED IMPACT OF NIRSEVIMAB FOR RSV PROPHYLAXIS IN THE PUBLIC HEALTHCARE SYSTEM OF CHILE
    Balmaceda, C.
    Armijo, N.
    Vera, M.
    Espinoza, M. A.
    VALUE IN HEALTH, 2024, 27 (12) : S93 - S94
  • [35] BUDGET IMPACT ANALYSIS OF ADOPTING EVOLOCUMAB IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM FOR PATIENTS WITH UNCONTROLLED LDL-C AND HIGH CARDIOVASCULAR RISK
    dos Santos, R. E.
    Alves, F. P.
    Urbich, M.
    Villa, G.
    Farsky, P. S.
    VALUE IN HEALTH, 2017, 20 (09) : A914 - A915
  • [36] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
    Escobar, Miguel
    Bullano, Michael
    Mokdad, Ali G.
    Caicedo, Jorge
    Schultz, Bob G.
    Fan, Qi
    Verma, Sumit
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
  • [37] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A BUDGET IMPACT ANALYSIS UNDER THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM
    Oliveira, L. E.
    Caires, A. L.
    Abreu, G. R.
    Nita, M. E.
    VALUE IN HEALTH, 2017, 20 (05) : A156 - A156
  • [38] BUDGET IMPACT ANALYSIS OF ZOLEDRONIC ACID IN POST MENOPAUSAL OSTEOPOROSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM
    Suzuki, C.
    Navarro, J.
    Pepe, C.
    VALUE IN HEALTH, 2009, 12 (07) : A522 - A522
  • [39] Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea
    Lee, Hankil
    Cho, Hyeonseok
    Han, Jung Woo
    Kim, Ah-Young
    Park, Seonyoung
    Lee, Minjun
    Cho, Sunghwa
    Baik, Deborah
    Kang, Hye-Young
    HAEMOPHILIA, 2021, 27 (01) : E12 - E21
  • [40] RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB
    Giacomini, E.
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2023, 26 (12) : S69 - S69
12345